Microphysiological systems (MPS) incorporating microfluidic technologies offer improved physiological relevance and real-time analysis for cell-based assays, but often lack non-invasive monitoring capabilities. Addressing this gap, we developed a microfluidic cell-based assay platform integrating an electrochemical biosensor for real-time, non-invasive monitoring of kinetic cell status through glucose consumption. The platform addresses the critical limitations of traditional cell assays, which typically rely on invasive, discontinuous methods. By combining enzyme-modified platinum electrodes within a microfluidic device, our biosensor can quantify dynamic changes in glucose concentration resulting from cellular metabolism. We have integrated a calibration function that corrects sensor drift, ensuring accurate and prolonged short-term measurement stability. In the validation experiments, the system successfully monitored glucose levels continuously for 20 h, demonstrating robust sensor performance and reliable glucose concentration predictions. Furthermore, in the cell toxicity assays using HepG2 cells exposed to varying concentrations of paraquat, the platform detected changes in glucose consumption, effectively quantifying the cellular toxicity responses. This capability highlights the device’s potential for accurately assessing the dynamic physiological conditions of the cells. Overall, our integrated platform significantly enhances cell-based assays by enabling continuous, quantitative, and non-destructive analysis, positioning it as a valuable tool for future drug development and biomedical research.
Microphysiological systems (MPSs) have emerged as alternatives to animal testing in drug development, following the FDA Modernization Act 2.0. Double-layer channel-type MPS chips with porous membranes are widely used for modeling various organs, including the intestines, blood–brain barrier, renal tubules, and lungs. However, these chips faced challenges owing to optical interference caused by light scattering from the porous membrane, which hinders cell observation. Trans-epithelial electrical resistance (TEER) measurement offers a non-invasive method for assessing barrier integrity in these chips. However, existing electrode-integrated MPS chips for TEER measurement have non-uniform current densities, leading to compromised measurement accuracy. Additionally, chips made from polydimethylsiloxane have been associated with drug absorption issues. This study developed an electrode-integrated MPS chip for TEER measurement with a uniform current distribution and minimal drug absorption. Through a finite element method simulation, electrode patterns were optimized and incorporated into a polyethylene terephthalate (PET)-based chip. The device was fabricated by laminating PET films, porous membranes, and patterned gold electrodes. The chip’s performance was evaluated using a perfused Caco-2 intestinal model. TEER levels increased and peaked on day 5 when cells formed a monolayer, and then they decreased with the development of villi-like structures. Concurrently, capacitance increased, indicating microvilli formation. Exposure to staurosporine resulted in a dose-dependent reduction in TEER, which was validated by immunostaining, indicating a disruption of the tight junction. This study presents a TEER measurement MPS platform with a uniform current density and reduced drug absorption, thereby enhancing TEER measurement reliability. This system effectively monitors barrier integrity and drug responses, demonstrating its potential for non-animal drug-testing applications.
Microphysiological systems (MPS) have emerged as alternatives to animal testing in drug development, following the FDA Modernization Act 2.0. Double-layer channel-type MPS chips with porous membranes are versatile for modeling various organs, including the intestines, blood-brain barrier, renal tubules, and lungs. However, these chips faced challenges owing to optical interference caused by light scattering from the porous membrane, which hinders cell observation. One non-invasive method for assessing barrier integrity in these chips is trans-epithelial electrical resistance (TEER) measurement. Existing electrode-integrated MPS chips for TEER measurement have non-uniform current densities, leading to compromised measurement accuracy. Additionally, chips made from polydimethylsiloxane have been associated with drug absorption issues. This study developed an electrode-integrated MPS chip for TEER measurement with uniform current distribution and minimal drug absorption. Through finite element method simulation, electrode patterns were optimized and incorporated into a polyethylene terephthalate (PET)-based chip. The device was fabricated by laminating PET films, porous membranes, and patterned gold electrodes. The chip’s performance was evaluated using a perfused Caco-2 intestinal model. TEER levels peaked on day 5 when cells formed a monolayer, then decreased as villi-like structures developed. Capacitance increased, indicating microvilli formation. Exposure to staurosporine resulted in a dose-dependent reduction in TEER, which was validated by immunostaining indicating tight junction disruption. This study presents a TEER measurement MPS platform with uniform current density and reduced drug absorption, thereby enhancing TEER measurement reliability. This system effectively monitors barrier integrity and drug responses, demonstrating its potential for non-animal drug-testing applications.
Microphysiological systems (MPS) incorporating microfluidic technologies offer improved physiological relevance and real-time analysis for cell-based assays, but often lack non-invasive monitoring capabilities. Addressing this gap, we developed a microfluidic cell-based assay platform integrating an electrochemical biosensor for real-time, non-invasive monitoring of kinetic cell status through glucose consumption. The platform addresses the critical limitations of traditional cell assays, which typically rely on invasive, discontinuous methods. By combining enzyme-modified platinum electrodes within a microfluidic device, our biosensor can quantify dynamic changes in glucose concentration resulting from cellular metabolism. We have integrated a calibration function that corrects sensor drift, ensuring accurate and long-term measurement stability. In validation experiments, the system successfully monitored glucose levels continuously for 20 h, demonstrating robust sensor performance and reliable glucose concentration predictions. Furthermore, in cell toxicity assays using HepG2 cells exposed to varying concentrations of paraquat, the platform detected changes in glucose consumption, effectively quantifying cellular toxicity responses. This capability highlights the device's potential for accurately assessing the dynamic physiological conditions of cells. Overall, our integrated platform significantly enhances cell-based assays by enabling continuous, quantitative, and non-destructive analysis, positioning it as a valuable tool for future drug development and biomedical research.